person
as of 2026-07-01Mark Weiser, MD
Mark Weiser, Dr
at a glance
Roles: Principal Investigator, Author
KOL signal score 9
2 publications · 0 high-value
Cross-drug reach: 2 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Sheba Medical Center
Roles
Principal Investigator, Author
KOL signal
9
Publications
2 (0 high-value)
Trial investigator
yes
Publishes on
2 drugs
Trials led
7
Cognitive Impairments in Psychotic Disorders
NCT05597579—Unknown
Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia
NCT00864825Phase 4Completed
Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder
NCT01280305Phase 3Unknown
Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone
NCT00480844Phase 4Unknown
Administrating Oxytocin to Treat Treatment Schizophrenia and Schizo-affective Patients
NCT01598623Phase 2Unknown
Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder
NCT01320982Phase 3Unknown
Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia
NCT00138775Phase 2Unknown
Publications & congress
2
Xanomeline/trospium and suicide-related events in schizophrenia: An early pharmacovigilance analysis.
Schizophrenia research · 2026
Association of Complement and Coagulation Pathway Proteins With Treatment Response in First-Episode Psychosis: A Longitudinal Analysis of the OPTiMiSE Clinical Trial.
Schizophrenia bulletin · 2023
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on
PRINCIPAL_INVESTIGATOR